<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179633</url>
  </required_header>
  <id_info>
    <org_study_id>OP001</org_study_id>
    <nct_id>NCT01179633</nct_id>
  </id_info>
  <brief_title>Acne Treatment With Active Patches Which Contains Azelaic Acid, Citric Acid,Salicylic Acid and 2% Ascorbic Acid</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oplon-Pure Science Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oplon-Pure Science Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to demonstrate the effect of short treatment with active OPLON&#xD;
      patches on Acne.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Acne Vulgaris were treated overnight with active patches. Effect is observed at&#xD;
      the end of the treatment and 24 hours later.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity Score of lesion</measure>
    <time_frame>•Severity Score of lesion [Time Frame: 24 hours following patch removal]</time_frame>
    <description>Lesions were ranked by investigator according to severity whereas:&#xD;
0-clear, 1-mild, 2-moderate, 3-sever</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity Score of lesion</measure>
    <time_frame>•Severity Score of lesion [Time Frame: 12 hours with the patch]</time_frame>
    <description>0-clear, 1-mild, 2-moderate, 3-sever</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Oplon Active Patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OPLON active patch</intervention_name>
    <arm_group_label>Oplon Active Patch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham patch</intervention_name>
    <arm_group_label>Placebo patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acne Vulgaris&#xD;
&#xD;
          -  Over 18 years&#xD;
&#xD;
          -  Signing informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active treatment of acne&#xD;
&#xD;
          -  Change in hormonal therapy&#xD;
&#xD;
          -  Antibiotic treatment in a week prior to the experiment&#xD;
&#xD;
          -  Sensitive skin&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avner Shemer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laniado Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Clinic</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <last_update_submitted>August 10, 2010</last_update_submitted>
  <last_update_submitted_qc>August 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Avner Shemer</name_title>
    <organization>Dermatology Clinic</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

